Avalo Therapeutics Inc.

Avalo Therapeutics Inc.

Market Cap (Aug-2026)
1.051 Billion USD
Market Cap (Mar-08-2026)
0.320 Billion USD
World Rank (Jan-05-2024)
31,979
Market Cap (Jan-05-2024)
0.007 Billion USD
World Rank (Jul-30-2023)
33,602
Market Cap (Jul-30-2023)
0.003 Billion USD
World Rank (Jan-07-2022)
21,658
Market Cap (Jan-07-2022)
0.117 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
AVTX
Headquarters City/State
Maryland
World Region
Americas
World Subregion
Northern America
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
AVALO THERAPEUTICS, INC.
Company Profile
Avalo Therapeutics, Inc. is a biopharmaceutical company that discover, develop and commercialize highly targeted therapeutics in areas of significant unmet clinical need. The headquarters is in USA.
Facts About Company
Avalo Therapeutics, Inc. company annual revenue is 18 million USD and annual net loss -41 million USD as on Dec-2022.
IPO Year
2015
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share